PDF下载 ( 1550 KB)
How to evaluate combination therapy using interferon and nucleos(t)ide analogues
-
摘要:
慢性乙型肝炎目前仍然是影响我国人民健康的重要疾病,主要原因是与其相关的肝硬化和肝细胞癌。目前治疗慢性乙型肝炎的药物主要有干扰素与核苷和核苷酸类药物,2种方法都各自存在着优缺点,进一步寻找和探索联合治疗是目前慢性乙型肝炎治疗的重要方向。分析了各类联合治疗的进展,针对目前联合治疗方法及患者的选择提出了意见。
Abstract:Chronic hepatitis B is still one of the most important chronic diseases in China because of its high relevance to liver cirrhosis and hepatic cell cancer( HCC). Currently,interferon and nucleos( t) ide analogues are two main treatments for chronic hepatitis B,but they have advantages and disadvantages. More investigations are needed to explore better ways for treating this disease,and combination therapy might be one of the options. This article analyzes the advances in various combination therapies and points out views about the selection of combination therapies and patients.
-
Key words:
- hepatitis B,chronic /
- interferons /
- nucleosides /
- nucleotides /
- drug therapy,combination
-
[1]SI CW.Current status and problem of chronic hepatitis B[J].Clin Med J,2006,4(4):1-2.(in Chinese)斯崇文.慢性乙型肝炎的现状和问题[J].临床药物治疗杂志,2006,4(4):1-2. [2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960. [3]SU TH,KAO JH.Improving clinical outcomes of chronic hepatitis B virus infection[J].Expert Rev Gastroenterol Hepatol,2015,9(2):141-154. [4]PETERSEN J,DANDRI M.Optimal therapy for chronic hepatitis B:hepatitis B virus combination therapy?[J].Liver Int,2015,35(Suppl 1):114-120. [5]LIN CL,KAO JH.Review article:novel therapies for hepatitis B virus cure-advances and perspectives[J].Aliment Pharmacol Ther,2016,44(3):213-222. [6]YAPALI S,TALAAT N,LOK AS.Management of hepatitis B:our practice and how it relates to the guidelines[J].Clin Gastroenterol Hepatol,2014,12(1):16-26. [7]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B[J].J Hepatol,2009,50(2):227-242. [8]ALLWEISS L,VOLZ T,LUTGEHETMANN M,et al.Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration[J].J Hepatol,2014,60(3):500-507. [9]MARCELLIN P,AHN SH,MA X,et al.Combination of tenofovir disoproxil fumarate and peginterferonα-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J].Gastroenterology,2016,150(1):134-144.e10. [10]MARCELLIN P,LAU GK,BONINO F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeA g-negative chronic hepatitis B[J].N Engl J Med,2004,351(12):1206-1217. [11]LAU GKK,PIRATVISUTH T,LUO KX,et al.Peginterferon alfa-2a,lamivudine,and the combination for HBeA g-positive chronic hepatitis B[J].N Engl J Med,2005,352(26):2682-2695. [12]JANSSEN HL,van ZONNEVELD M,SENTURK H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeA g-positive chronic hepatitis B:a randomised trial[J].Lancet,2005,365(9454):123-129. [13]TAKKENBERG RB,JANSEN L,de NIET A,et al.Baseline hepatitis B surface antigen(HBs Ag)as predictor of sustained HBs Ag loss in chronic hepatitis B patients treated with Pegylated interferon-alpha2a and adefovir[J].Antivir Ther,2013,18(7):895-904. [14]XIE Q,ZHOU H,BAI X,et al.A randomized,open-label clinical study of combined Pegylated interferon alfa-2a(40KD)and entecavir treatment for hepatitis B“e”antigenpositive chronic hepatitis B[J].Clin Infect Dis,2014,59(12):1714-1723. [15]PICCOLO P,LENCI I,DEMELIA L,et al.A randomized controlled trial of Pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B[J].Antivir Ther,2009,14(8):1165-1174. [16]FAN R,SUN J,HOU JL.Combination therapy with tenofovir and Peginterferon may not be translated into current clinical practice[J].Gastroenterology,2016,150(5):1253-1254. [17]BROUWER WP,XIE Q,SONNEVELD MJ,et al.Adding Pegylated interferon to entecavir for hepatitis B e antigenpositive chronic hepatitis B:a multicenter randomized trial(ARES study)[J].Hepatology,2015,61(5):1512-1522. [18]HENG C,XIE Q,ZHANG NP,et al.Addition of peginterferon alfa-2b during long-term nucleos(t)ide analogue therapy increases HBeA g seroconversion and HBsA g decline-week 48results from a multicenter randomized controlled trial[C].AASLD 2014,Abstract#1882. [19]BOURLIERE M,RABIEGA P,GANNE-CARRIE N,et al.HBsA g clearance after addition of 48 weeks of PEGIFN in HBeA g negative CHB patients on Nucleos(t)ide therapy with undetectable HBV DNA for at least one year:a multicenter randomized controlled phase III trial ANRS-HB06 PEGAN study:preliminary findings[C].AASLD 2014,Abstract#1863. [20]LAMPERTICO P,BRUNETTO MR,CRAXI A,et al.Add-on PEGinterferon Alfa-2a significantly reduces HBsA g levels in HBeA g-negative,genotype D chronic hepatitis B patients fully suppressed on nucleot(s)ide analogues treatment:final results of the HERMES study[C].EASL 2016,Abstract#LBP 521. [21]SPRINZL MF,GRAMBIHLER A,TEUBER G,et al.Add on interferon-alpha-2a for the treatment of HBeA g negative hepatitis B patients receiving effective nucleos(t)ide therapy:interim results of the prospective multicenter PADD-ON trial[C].EASL 2016,Abstract#LBP 517. [22]NING Q,HAN M,SUN Y,et al.Switching from entecavir to PegI FN alfa-2a in patients with HBeA g-positive chronic hepatitis B:a randomised open-label trial(OSST trial)[J].J Hepatol,2014,61(4):777-784. [23]SUN J,MA H,XIE Q,et al.Response-guided Peginterferon therapy in patients with HBeA g-positive chronic hepatitis B:a randomized controlled study[J].J Hepatol,2016,65(4):674-682. [24]PENG H,WEI F,LIU JY,et al.Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification:a meta-analysis[J].Hepatol Int,2015,9(4):543-557. -
本文二维码
计量
- 文章访问数: 2439
- HTML全文浏览量: 7
- PDF下载量: 498
- 被引次数: 0
下载:
